Therapeutic repurposing of old drugs to modulate the tumor immune microenvironment and enhance immunotherapy efficacy
Abstract
Although immunotherapy has demonstrated remarkable progress in cancer treatment, its clinical benefits remain restricted to a subset of patients and specific cancer types, primarily due to the immunosuppressive nature of the tumor microenvironment (TME) in solid tumors. Therefore, many strategies have focused on targeting the immunosuppressive TME to enhance immune-mediated tumor eradication. In parallel, the repositioning of old drugs represents an attractive discovery approach compared with the traditional de novo drug discovery process, which is time-consuming and costly. Thus, repurposing US Food and Drug Administration (FDA)-approved old drugs to modulate the tumor immune microenvironment represents a promising strategy to augment the effectiveness of cancer immunotherapy. Indeed, emerging evidence indicates that several approved drugs can reprogram the tumor immune landscape, thereby enhancing responses to immunotherapy. This review provides a comprehensive overview of US FDA-approved old drugs with immunomodulatory properties in the tumor context. We discuss their mechanisms in reversing immunosuppression, summarize key findings from preclinical studies and clinical trials involving their combination with immunotherapies, and outline future perspectives for their clinical translation. Collectively, this work highlights the translational potential of drug repurposing as a strategy to expand the therapeutic reach of cancer immunotherapy.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.